Anatomic and Cellular Niches for <i>Mycobacterium tuberculosis</i> in Latent Tuberculosis Infection

Mayito, Jonathan; Andia, Irene; Belay, Mulugeta; Jolliffe, David A.; Kateete, David Patrick; Reece, Stephen T.; Martineau, Adrian R.

doi:10.1093/infdis/jiy579

Cited by 41 publications

(46 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2017) and bone marrow (Mayito et al . 2019) have been proposed as extrapulmonary niches where the tubercle bacillus could persist for long periods of time modulating the local tissue environment.…”

Section: From Tissues To Phagosomes: the Environments Mtb Faces In Thmentioning

confidence: 99%

Mycobacterium tuberculosisinfection of host cells in space and time

Bussi

Gutierrez

2019

FEMS Microbiology Reviews

263

156

View full text Add to dashboard Cite

Tuberculosis (TB) caused by the bacterial pathogen Mycobacterium tuberculosis (Mtb) remains one of the deadliest infectious diseases with over a billion deaths in the past 200 years (Paulson 2013). TB causes more deaths worldwide than any other single infectious agent, with 10.4 million new cases and close to 1.7 million deaths in 2017. The obstacles that make TB hard to treat and eradicate are intrinsically linked to the intracellular lifestyle of Mtb. Mtb needs to replicate within human cells to disseminate to other individuals and cause disease. However, we still do not completely understand how Mtb manages to survive within eukaryotic cells and why some cells are able to eradicate this lethal pathogen. Here, we summarise the current knowledge of the complex host cell-pathogen interactions in TB and review the cellular mechanisms operating at the interface between Mtb and the human host cell, highlighting the technical and methodological challenges to investigating the cell biology of human host cell-Mtb interactions.

show abstract

Section: From Tissues To Phagosomes: the Environments Mtb Faces In Thmentioning

confidence: 99%

Mycobacterium tuberculosisinfection of host cells in space and time

Bussi

Gutierrez

2019

FEMS Microbiology Reviews

263

156

View full text Add to dashboard Cite

show abstract

“…The hypoxic microenvironment of stem cell niche may favor Mtb dormancy ( 76 , 77 ) and resistance against anti TB drugs ( 56 , 57 ). All these reasons unite to make BM stem cells a potential niche for Mtb during LTBI ( 27 ). Interestingly, stem cell’s self-renewal property is utilized by other bacteria, including Mycobacterium leprae ( 78 ) and Wolbachia ( 79 ) for effective transmission.…”

Section: Bone Marrow (Bm) Stem Cell Niche As the Site Of Dormant mentioning

confidence: 99%

“…Following our initial findings, many laboratories not only reproduced our findings but also added important information about the Mtb /human BM-stem cell host-pathogen interaction ( 24 – 26 ). These findings raise human bone marrow derived stem cells as the site of Mtb latency ( 27 ). Recently, we have shown that stem cell altruism may be involved in Mtb -reactivation ( 28 ), and in the aerosol-induced immunity ( 29 ).…”

Section: Introductionmentioning

confidence: 95%

Initiation of Post-Primary Tuberculosis of the Lungs: Exploring the Secret Role of Bone Marrow Derived Stem Cells

Pathak

Das

2021

Front. Immunol.

View full text Add to dashboard Cite

Mycobacterium tuberculosis (Mtb), the causative organism of pulmonary tuberculosis (PTB) now infects more than half of the world population. The efficient transmission strategy of the pathogen includes first remaining dormant inside the infected host, next undergoing reactivation to cause post-primary tuberculosis of the lungs (PPTBL) and then transmit via aerosol to the community. In this review, we are exploring recent findings on the role of bone marrow (BM) stem cell niche in Mtb dormancy and reactivation that may underlie the mechanisms of PPTBL development. We suggest that pathogen’s interaction with the stem cell niche may be relevant in potential inflammation induced PPTBL reactivation, which need significant research attention for the future development of novel preventive and therapeutic strategies for PPTBL, especially in a post COVID-19 pandemic world. Finally, we put forward potential animal models to study the stem cell basis of Mtb dormancy and reactivation.

show abstract

“…Mtb-specific CD4+ T-cell activation markers in blood may discriminate pulmonary and extrapulmonary TB from LTBI (Silveira-Mattos et al, 2019). Recently, Mtb has been demonstrated in mesenchymal and hematopoietic stem cells (Mayito et al, 2019); thus whole genome sequencing of bone marrow specimens from LTBI patients may show the presence of Mtb with rpo gene mutations in stem cell CD34 populations.…”

Section: Advancing Ltbi Diagnostic Testsmentioning

confidence: 99%

Advancing new diagnostic tests for latent tuberculosis infection due to multidrug-resistant strains of Mycobacterium tuberculosis — End of the road?

Mwaba

Chakaya

Petersen

et al. 2020

International Journal of Infectious Diseases

View full text Add to dashboard Cite

A B S T R A C TAn estimated 1.8 billion people worldwide have a latent tuberculosis infection (LTBI), with wide variations in LTBI rates across countries. LTBI can be due to infection with either drug-sensitive or drugresistant Mycobacterium tuberculosis (Mtb) strains. Accurate data on the prevalence of LTBI due to multidrug-resistant (MDR) Mtb strains are unavailable, since the strains cannot be isolated for resistance testing. There are no 'gold standard' tests for accurately diagnosing LTBI. Only three tests are currently available and approved by the World Health Organization (WHO) for the diagnosis of LTBI: the now outdated tuberculin skin test (TST), developed a century year ago, and the two interferon-gamma release assays (IGRAs) developed and rolled out over the past decade, the QuantiFERON (Qiagen, Germany) and T-SPOT.TB (Oxford Immunotec, United Kingdom) tests. These latter tests are not ideal due to issues of sensitivity, specificity, inability to distinguish infection with MDR-Mtb strains, and high costs. Achieving the WHO End TB Strategy target of an 80% reduction in global TB incidence by 2030 will require a major reduction in the number of persons with LTBI progressing to active TB disease. Critical to this will be the development of new diagnostic tests that are better than currently available LTBI tests at predicting who is at risk of progression to active TB disease. The diagnostic product development portfolio for LTBI appears to have reached the end of the road. Every attempt to make optimal use of currently available IGRAs using WHO LTBI guidelines for LTBI testing and treatment must be made to achieve WHO End TB strategy targets.

show abstract

Anatomic and Cellular Niches for Mycobacterium tuberculosis in Latent Tuberculosis Infection

Cited by 41 publications

References 78 publications

Mycobacterium tuberculosisinfection of host cells in space and time

Mycobacterium tuberculosisinfection of host cells in space and time

Initiation of Post-Primary Tuberculosis of the Lungs: Exploring the Secret Role of Bone Marrow Derived Stem Cells

Advancing new diagnostic tests for latent tuberculosis infection due to multidrug-resistant strains of Mycobacterium tuberculosis — End of the road?

Contact Info

Product

Resources

About